Brief description of included randomized trials.

NSCLC: non-small-cell lung cancer; RCC: renal cell carcinoma; SCLC: small-cell lung cancer; FOLFOX 4: oxaliplatin, leucovorin, fluorouracil; FU/LV:fluorouracil & leucovorin; IFL: irinotecan, bolus fluorouracil, leucovorin; XELOX: capecitabine & oxaliplatin; HAI Hepatic arterial infusion
$Comparison between another arm and control was not eligible.
There are 74 rows for 72 studies reported in text: two studies, Martin 2011 had two arms Motesanib and bevacizumab comparing with placebo, Robert 2011 had two arms of capecitabine and taxane-based/anthracycline-based comparing bevacizumab versus placebo in each arm.
*These are two different trials published in the same year by the same author: Spigel et al in 2011 used bevacizumab for extensive stage small cell lung cancer in one trial and sorafenib for advanced non–small-cell lung cancer in another trial. Likewise, Escudier et al in 2007 used neovastat in metastatic renal cell carcinoma in one trial and sorafenib in advanced clear-cell renal-cell carcinoma in another trial.